Bio-Rad acquires AbD Serotec
15 January, 2013Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products, has announced that it has purchased AbD Serotec, a division of MorphoSys AG, for approximately €53 million in cash.
Academic and biotechnology industry alliance wins $300,000 grant
15 January, 2013The Victorian Government has provided $300,000 to the Victorian Infection and Immunity Network (VIIN) as part of its Collaborative Networks Pilot Program to encourage the development of partnerships between academic and industry groups and to accelerate industry’s adoption of new technologies.
New appointments at the Australian Synchrotron
14 January, 2013The Australian Nuclear Science and Technology Organisation (ANSTO) has announced a series of new appointments at the Australian Synchrotron.
UNSW secures Australia-China joint research centre
19 December, 2012The University of New South Wales (UNSW) has secured funding for one of six new Australia-China joint research centres, which aims to meet the challenges facing the minerals, metallurgy and materials industries in both countries.
Industry sponsorship leads to bias in reported findings of clinical trials
14 December, 2012Studies reporting the results of industry-sponsored clinical trials present a more favourable picture of the effects of drugs and medical devices than those reporting on non-industry-sponsored trials, according to a Cochrane systematic review.
A new era of science partnership between Australia and China
14 December, 2012The Australian Nuclear Science and Technology Organisation (ANSTO) has welcomed the signing of a research agreement celebrating the 40th anniversary of diplomatic relationships between Australia and China.
2013 BIO International Convention: call for expressions of interest
12 December, 2012The 2013 Australian Delegation to biotechnology convention BIO, being managed by AusBiotech, gives Australian companies and research organisations a chance to participate on the Australian pavilion at the event.
Renewed agreement opens paths to better science for Australia and India
05 December, 2012Scientists in Australia and India can look forward to greater levels of cooperation and collaboration after the Australian Academy of Science and Indian National Academy of Science today renewed their commitment to work more closely together.
Big Pharma doing more for access to medicine in developing countries than two years ago
30 November, 2012The latest Access to Medicine Index, which ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in developing countries, finds that the industry is doing more than it was two years ago.
Scientist’s sons sue CIA over covert mind control testing and murder
30 November, 2012In the 1950s and 60s, the CIA was covertly administering LSD to US citizens as it attempted to develop mind control technologies. One family is now alleging murder.
New policy brings clarity and consistency to drug names
29 November, 2012To provide greater clarity and consistency in naming practices for medicines, a new drug naming policy established by the United States Pharmacopeial Convention (USP) will become official on 1 May 2013.
Chief Scientist welcomes the National Research Investment Plan
28 November, 2012Australia’s Chief Scientist and Australian Research Committee (ARCom) chairman Professor Ian Chubb has welcomed today’s launch of the National Research Investment Plan (NRIP).
Inaugural OMICS Australasia Symposium
27 November, 2012The inaugural OMICS Australasia 2012 Symposium is being held from 26-28 November in Fremantle, Western Australia. It is being hosted by Murdoch University and supported by the Western Australian Department of Commerce, Bruker and other industry sponsors.
Opportunities and rewards for researchers at the Australian Synchrotron
27 November, 2012Two Australian Synchrotron users are among the 12 winners of the prestigious Victoria Fellowships for 2012.
Biotech abandoning blockbuster drug model
26 November, 2012Biotech companies are exploring alternative options to supplement their in-house research and development, abandoning the traditional blockbuster drug model to instead pursue deals and buy their way to success, says new report.
